"[T]he knowledge and depth of the practice's bench for multi-faceted transactions is superb." - Legal 500
In recent years, Cadwalader has emerged as a leading mergers and acquisitions firm, with a nationally recognized team of attorneys that has been called on to handle some of the largest and most complex deals in the marketplace.
Providing assistance beginning at the earliest stages of a transaction, Cadwalader attorneys advise clients—buyers, sellers and financial advisors—in evaluating and developing alternative strategies for achieving business objectives, structuring and documenting deals, arranging financing, and obtaining regulatory approvals. We are known for our ability to structure and coordinate creative and complex transaction structures with long-term tax benefits, operating efficiencies, and enhanced rate of return and for our expertise in the areas of law that frequently affect mergers and acquisitions, such as antitrust; environmental; employee benefits; insolvency; tax; litigation; and securitization. In addition, we are proficient at coordinating and guiding other professionals, such as investment bankers, accountants, and actuaries, to complete transactions efficiently and effectively.
- Pershing Square Tontine Holdings in its $4 billion agreement to acquire 10% of the outstanding ordinary shares of Universal Music Group from Vivendi.
- one in its $2.1 billion business combination transaction with Markforged.
- Senator in its partnership with Cannae to make an approximately $7 billion unsolicited acquisition proposal for CoreLogic.
- Thoma Bravo Advantage in its $11.1 billion merger with ironSource.
- Corindus Vascular Robotics in its $1.1 billion acquisition by Siemens Healthineers.
- Forbes Media in its proposed $630 million business combination with Magnum Opus Acquisition and related $200 million strategic investment from Binance.
- Hudson Executive Capital in its agreement, along with Apollo, to acquire Cardtronics for $2.3 billion.
- Pfizer in its $68 billion acquisition of Wyeth; its $63.5 billion acquisition of Pharmacia; its $3.6 billion acquisition of King Pharmaceuticals; its $114.5 billion hostile takeover of Warner-Lambert; its $1.9 billion acquisition of Vicuron Pharmaceuticals; its $155 million acquisition of Embrex; its $16.6 billion sale of its consumer healthcare business to Johnson & Johnson; and its $2.4 billion sale of its Capsugel business to Kohlberg Kravis Roberts.
- Portico in its sale to Cowen.
- Inteva Products in the $800 million sale of its roof systems design and assembly business to CIE Automotive.
- AngioDynamics in its acquisitions of the BioSentry assets of Surgical Specialties and of RadiaDyne, Navilyst Medical, Microsulis Medical, Vortex Medical and Clinical Devices, and in the sale of its NAMIC® fluid management portfolio to Medline Industries.
- Cybereason in its acquisition of empow and in securing $275 million in crossover financing in an investment round led by Liberty Strategic Capital.
- The largest shareholder of LendingClub in its acquisition of Radius Bank, the first acquisition by a FinTech lender of a traditional bank.
- Integrity Implants (d/b/a Accelus) in its proposed $482 million business combination with CHP Merger Corporation.
- Towers Watson in its acquisitions of Acclaris, Extend Health and Liazon and in the sale of its reinsurance brokerage business to JLT.
- BW LPG in its proposal to acquire Dorian LPG.
- Genpact in its acquisitions of Barkawi, OnSource and TandemSeven.
- ACRES Capital in the acquisition of the external manager of public REIT Exantas Capital.
- Salix in its $15.6 billion acquisition by Valeant and previously in its terminated combination with Cosmo Technologies, a subsidiary of Cosmo Pharmaceuticals, to form Salix Pharmaceuticals, plc.
- Monocle Acquisition Corporation in its merger with AerSale.
- Ashford Inc. in its $275 million acquisition of Remington.
- JPMorgan as financial advisor to the Special Committee of the Board of Directors of Dell in its $24.9 billion acquisition by Michael Dell and Silver Lake Partners.
- Élan in its $8.6 billion sale to Perrigo, its successful defense of a $6.6 billion hostile tender offer by Royalty Pharma and its $3.25 billion sale of Tysabri rights to Biogen Idec.
- The Medicines Company in the $792 million sale of three of its marketed cardiovascular products and related assets to Chiesi Farmaceutici and in the sale of its infectious disease business to Melinta Therapeutics for $270 million and royalty payments on net sales of the pharmaceutical products sold to Melinta in the transaction.
- DPL in its $4.7 billion sale to AES.
- ELEAD1ONE in its approximately $650 million sale to CDK Global.
- New Mexico Health Connections in the sale of its commercial health insurance business to Evolent Health.
- Seacoast Bank in its acquisitions of Floridian Financial Group and GulfShore Bank.
- Burger King and its controlling stockholder, 3G Capital, in a business combination with Justice Holdings, a LSE-listed SPAC, resulting in a partial sale of Burger King to the Justice shareholders for $1.4 billion and a NYSE listing of Burger King.
- Community Health Systems in its $7.6 billion acquisition of Health Management Associates and $6.8 billion acquisition of Triad Hospitals.
- NRG Energy in its successful defense of a $7.45 billion hostile bid for the company by Exelon.
*Certain representations occurred prior to specific attorneys’ association with Cadwalader.
